Dimerization of LTβR by LTα1β2 is necessary and sufficient for signal transduction

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 49, 2013, Pages 19896-19901

  Sudhamsu, Jawahar ^a   Yin, JianPing ^a   Chiang, Eugene Y ^b   Starovasnik, Melissa A ^a   Grogan, Jane L ^b   Hymowitz, Sarah G ^b  

^a Departments of Structural Biology   (United States)

^b GENENTECH INC   (United States)

Author keywords

Biophysics; Crystallography; Cytokines; Mechanism

Indexed keywords

ANTIBODY; LYMPHOTOXIN ALPHA BETA; LYMPHOTOXIN BETA RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIMERIZATION; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; STATIC ELECTRICITY;

BIOPHYSICS; CRYSTALLOGRAPHY; CYTOKINES; MECHANISM;

CHROMATOGRAPHY, GEL; CYTOKINES; DIMERIZATION; HUMANS; LYMPHOTOXIN ALPHA1, BETA2 HETEROTRIMER; LYMPHOTOXIN BETA RECEPTOR; MULTIPROTEIN COMPLEXES; SIGNAL TRANSDUCTION;

EID: 84889646073     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1310838110     Document Type: Article

References (36)

1. Browning JL, et al. (1996) Preparation and characterization of soluble recombinant heterotrimeric complexes of human lymphotoxins alpha and beta. J Biol Chem 271(15):8618-8626.
2. Ware CF (2005) Network communications: Lymphotoxins, LIGHT, and TNF. Annu Rev Immunol 23:787-819.
3. Gommerman JL, Browning JL (2003) Lymphotoxin/light, lymphoid microenvironments and autoimmune disease. Nat Rev Immunol 3(8):642-655.
4. Tumanov AV, Kuprash DV, Nedospasov SA (2003) The role of lymphotoxin in development and maintenance of secondary lymphoid tissues. Cytokine Growth Factor Rev 14(3-4):275-288.
5. Grogan JL, Ouyang WJ (2012) A role for Th17 cells in the regulation of tertiary lymphoid follicles. Eur J Immunol 42(9):2255-2262.
6. Browning JL, et al. (1997) Characterization of lymphotoxin-alpha beta complexes on the surface of mouse lymphocytes. J Immunol 159(7):3288-3298.
7. Chiang EY, et al. (2009) Targeted depletion of lymphotoxin-alpha- expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med 15(7):766-773.
8. Gramaglia I, Mauri DN, Miner KT, Ware CF, Croft M (1999) Lymphotoxin alphabeta is expressed on recently activated naive and Th1-like CD4 cells but is down-regulated by IL-4 during Th2 differentiation. J Immunol 162(3):1333-1338.
9. Ware CF, Crowe PD, Grayson MH, Androlewicz MJ, Browning JL (1992) Expression of surface lymphotoxin and tumor necrosis factor on activated T, B, and natural killer cells. J Immunol 149(12):3881-3888.
10. Browning JL (2008) Inhibition of the lymphotoxin pathway as a therapy for autoimmune disease. Immunol Rev 223:202-220.
11. Chiang EY, et al. (2012) In vivo depletion of lymphotoxin-alpha expressing lymphocytes inhibits xenogeneic graft-versus-host-disease. PLoS ONE 7(3):e33106.
12. Li C, et al. (2003) Structurally distinct recognition motifs in lymphotoxin-beta receptor and CD40 for tumor necrosis factor receptor-associated factor (TRAF)-mediated signaling. J Biol Chem 278(50):50523-50529.
13. Wu H (2013) Higher-order assemblies in a new paradigm of signal transduction. Cell 153(2):287-292.
14. Jones EY, Stuart DI, Walker NPC (1989) Structure of tumour necrosis factor. Nature 338(6212):225-228.
15. Banner DW, et al. (1993) Crystal structure of the soluble human 55 kd TNF receptorhuman TNF beta complex: Implications for TNF receptor activation. Cell 73(3): 431-445.
16. Mongkolsapaya J, et al. (1999) Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. Nat Struct Biol 6(11):1048-1053.
17. Nelson CA, Warren JT, Wang MWH, Teitelbaum SL, Fremont DH (2012) RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor. Structure 20(11):1971-1982.
18. Zhan CY, et al. (2011) Decoy strategies: The structure of TL1A:DcR3 complex. Structure 19(2):162-171.
19. An HJ, et al. (2011) Crystallographic and mutational analysis of the CD40-CD154 complex and its implications for receptor activation. J Biol Chem286(13):11226-11235.
20. Compaan DM, Hymowitz SG (2006) The crystal structure of the costimulatory OX40- OX40L complex. Structure 14(8):1321-1330.
21. Mukai Y, et al. (2010) Solution of the structure of the TNF-TNFR2 complex. Sci Signal 3(148):ra83.
22. Ta HM, et al. (2010) Structure-based development of a receptor activator of nuclear factor-kappaB ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis. Proc Natl Acad Sci USA 107(47):20281-20286.
23. Hymowitz SG, et al. (1999) Triggering cell death: The crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell 4(4):563-571.
24. Karpusas M, et al. (2001) Structure of CD40 ligand in complex with the Fab fragment of a neutralizing humanized antibody. Structure 9(4):321-329.
25. Liang S, et al. (2013) Structural basis for treating tumor necrosis factor α (TNFα)- associated diseases with the therapeutic antibody infliximab. J Biol Chem 288(19): 13799-13807.
26. Goh CR, Loh CS, Porter AG (1991) Aspartic acid 50 and tyrosine 108 are essential for receptor binding and cytotoxic activity of tumour necrosis factor beta (lymphotoxin). Protein Eng 4(7):785-791.
27. Eldredge J, et al. (2006) Stoichiometry of LTbetaR binding to LIGHT. Biochemistry 45(33):10117-10128.
28. Browning JL, et al. (1993) Lymphotoxin beta, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface. Cell 72(6): 847-856.
29. Browning JL, et al. (1995) Characterization of surface lymphotoxin forms. Use of specific monoclonal antibodies and soluble receptors. J Immunol 154(1):33-46.
30. Ware CF (2013) Protein therapeutics targeted at the TNF superfamily. Adv Pharmacol 66:51-80.
31. Shapiro L, Scherer PE (1998) The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol 8(6):335-338.
32. Bogin O, et al. (2002) Insight into Schmid metaphyseal chondrodysplasia from the crystal structure of the collagen X NC1 domain trimer. Structure 10(2):165-173.
33. Schneider P, et al. (2001) Mutations leading to X-linked hypohidrotic ectodermal dysplasia affect three major functional domains in the tumor necrosis factor family member ectodysplasin-A. J Biol Chem 276(22):18819-18827.
34. Schneider P, et al. (1998) Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 187(8):1205-1213.
35. Tanaka M, Itai T, Adachi M, Nagata S (1998) Downregulation of Fas ligand by shedding. Nat Med 4(1):31-36.
36. Wang L, et al. (2010) The Fas-FADD death domain complex structure reveals the basis of DISC assembly and disease mutations. Nat Struct Mol Biol 17(11):1324-1329.